Safety largely depends on correct dosage, treatment method, and the quality of the formulation used
The resistant-starch ingredient's supplier or trade name was not fully legible on the physical label image supplied
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a Phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
Five GLP-1RAs are available in Australia (dulaglutide, exenatide BD, exenatide QW, liraglutide, and lixisenatide), one is undergoing regulatory approval (semaglutide), and three are currently available under the governments reimbursement scheme (dulaglutide, exenatide BD, and exenatide QW)
ImageJ v1.8.0 (National Institutes of Health) was used for Western blot densitometry analysis
It has a long history of use as an anti-nausea remedy and may help some with symptom relief